Float Short %

30.48

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

0.12

EPS Last/This Y

1.09

EPS This/Next Y

0.3

Price

9.37

Target Price

36.84

Analyst Recom

1.62

Performance Q

16.23

Relative Volume

0.61

Beta

2.21

Ticker: NTLA

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	NTLA	7.2	0.25	0.63	57660
2025-06-03	NTLA	7.68	0.26	1.40	58572
2025-06-04	NTLA	7.66	0.29	0.09	60074
2025-06-05	NTLA	7.57	0.29	0.21	60785
2025-06-06	NTLA	8.06	0.28	0.78	61213
2025-06-09	NTLA	8.26	0.25	1.59	60957
2025-06-10	NTLA	8.46	0.28	0.28	62955
2025-06-11	NTLA	8.36	0.28	0.18	63925
2025-06-12	NTLA	8.35	0.29	0.67	64003
2025-06-13	NTLA	8.31	0.31	0.01	65024
2025-06-16	NTLA	8.97	0.29	0.25	67537
2025-06-17	NTLA	9.59	0.29	1.08	67582
2025-06-18	NTLA	9.6	0.31	0.96	68338
2025-06-20	NTLA	9.19	0.33	0.40	69743
2025-06-23	NTLA	9.23	0.35	0.09	59985
2025-06-24	NTLA	9.56	0.30	0.13	58726
2025-06-25	NTLA	9.56	0.29	0.24	59385
2025-06-26	NTLA	9.6	0.29	0.11	59721
2025-06-27	NTLA	9.56	0.28	0.54	60965
2025-06-30	NTLA	9.36	0.28	0.06	61383
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	NTLA	7.15	32.4	-80.9	-4.24
2025-06-03	NTLA	7.69	32.4	-103.3	-4.24
2025-06-04	NTLA	7.66	32.4	-13.4	-4.24
2025-06-05	NTLA	7.58	32.4	-5.0	-4.24
2025-06-06	NTLA	8.06	33.3	-89.8	-4.16
2025-06-09	NTLA	8.28	33.3	-41.2	-4.16
2025-06-10	NTLA	8.46	33.3	-39.4	-4.16
2025-06-11	NTLA	8.36	33.3	-4.9	-4.16
2025-06-12	NTLA	8.35	33.3	-14.7	-4.16
2025-06-13	NTLA	8.31	33.3	-11.7	-4.16
2025-06-16	NTLA	8.97	33.3	-97.5	-4.16
2025-06-17	NTLA	9.58	33.3	-84.1	-4.16
2025-06-18	NTLA	9.60	33.3	-19.7	-4.16
2025-06-20	NTLA	9.20	33.3	20.2	-4.16
2025-06-23	NTLA	9.24	33.3	-23.3	-4.16
2025-06-24	NTLA	9.56	33.3	-51.5	-4.16
2025-06-25	NTLA	9.55	33.3	-16.0	-4.16
2025-06-26	NTLA	9.59	33.3	-21.7	-4.16
2025-06-27	NTLA	9.56	33.3	-13.0	-4.16
2025-06-30	NTLA	9.37	33.3	0.3	-4.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	NTLA	-1.16	2.23	31.50
2025-06-03	NTLA	-1.16	2.23	31.50
2025-06-04	NTLA	-1.16	2.23	31.50
2025-06-05	NTLA	-1.16	2.23	31.50
2025-06-06	NTLA	-1.17	2.23	31.50
2025-06-09	NTLA	-1.16	2.23	31.50
2025-06-10	NTLA	-1.16	2.23	31.50
2025-06-11	NTLA	-1.16	2.23	32.37
2025-06-12	NTLA	-1.16	2.23	32.37
2025-06-13	NTLA	-1.16	2.23	32.37
2025-06-16	NTLA	-1.16	2.27	32.37
2025-06-18	NTLA	-1.16	2.27	32.37
2025-06-20	NTLA	-1.16	2.27	32.37
2025-06-23	NTLA	-1.16	2.27	32.39
2025-06-24	NTLA	-1.16	2.27	32.39
2025-06-25	NTLA	-1.16	2.27	32.39
2025-06-26	NTLA	-1.16	2.27	30.48
2025-06-27	NTLA	-1.16	2.27	30.48
2025-06-30	NTLA	-1.16	2.33	30.48
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.1

Avg. EPS Est. Current Quarter

-1.01

Avg. EPS Est. Next Quarter

-0.98

Insider Transactions

-1.16

Institutional Transactions

2.33

Beta

2.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.4

Max Drawdown 5-Year %

-96.4

Target Price

36.84

P/E

Forward P/E

PEG

P/S

21.32

P/B

1.25

P/Free Cash Flow

EPS

-5.23

Average EPS Est. Cur. Y

-4.16

EPS Next Y. (Est.)

-3.86

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1154.1

Relative Volume

0.61

Return on Equity vs Sector %

-91.3

Return on Equity vs Industry %

-72.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

0.3

Intellia Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 403

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

stock quote shares NTLA – Intellia Therapeutics, Inc. Stock Price stock today

news today NTLA – Intellia Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NTLA – Intellia Therapeutics, Inc. yahoo finance google finance

stock history NTLA – Intellia Therapeutics, Inc. invest stock market

stock prices NTLA premarket after hours

ticker NTLA fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NTLA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y